Evidence map›Paper›PMID 42706261›Full record

ArticleNature communications2026

Adaptive oncogenesis of β-catenin emerges from declining liver tissue integrity.

Abhinav Illendula, Charles K Hewett, Yuki Hayata, Lauren S Strathearn, Guoshun He, Laia Carballo-Botinas, Sara Navas-Sanz, Maria Niqui-Capdevila, Avril Garcia-Santos, Rocío Bernabé-Pérez and 12 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Abhinav Illendula *Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0004-8245-7211
Charles K Hewett *Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Yuki Hayata *Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Lauren S StrathearnCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Guoshun HeCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Laia Carballo-BotinasCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0007-7498-5219
Sara Navas-SanzCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0005-4941-8429
Maria Niqui-CapdevilaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0008-9462-8080
Avril Garcia-SantosCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Rocío Bernabé-PérezCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Alejandra Bustillo-BustosCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Ani MikoyanCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0009-7818-2784
Eleanor HelmCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Marina Gonzalez-SorribesCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Nicola de PriscoCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Aasthika DasCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Yuanguangyan ZhangCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
David RossellDepartment of Economics, Universitat Pompeu Fabra, Barcelona, Spain.
Michael SlifkerBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.
Naiara AkizuRaymond G. Perelman Center for Cellular and Molecular Therapeutics and Center for Brain Research In Development, Genetics and Engineering, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9222-6960
Beicheng SunDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID http://orcid.org/0000-0002-8657-7024
Joan Font-BurgadaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. joan.font-burgada@fccc.edu.ORCID http://orcid.org/0000-0003-3372-418X

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
New tools for understanding metastasis through tissue resident cells: enabling an Extensive Medicine strategy for metastatic diseaseDP2CA258224 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI FONT-BURGADA, JOAN · 2020 to 2020
$2.8M
Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced OncogenesisR01CA289703 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Joan Font-Burgada · 2024 to 2026
$1.7M
Development of mosaic mouse models of HCC for genetic interspecies inferenceR00CA191152 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI FONT-BURGADA, JOAN · 2017 to 2019
$747k
Development of mosaic mouse models of HCC for genetic interspecies inferenceK99CA191152 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FONT-BURGADA, JOAN · 2015 to 2016
$219k
NCI NIH HHS DP2 CA258224NCI NIH HHS K99 CA191152NCI NIH HHS P30 CA006927NCI NIH HHS R00 CA191152NCI NIH HHS R01 CA289703U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA191152U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA258224U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA289703
6 · The paper itself

Abstract

Mutations are fundamental to oncogenesis, yet they cannot fully explain cancer progression, as oncogenic mutations frequently accumulate in healthy tissues without immediate malignancy. In the liver, β-catenin mutations are highly prevalent in hepatocellular carcinoma but are widely considered weak or cooperative drivers, raising the question of how their oncogenic potential is contextually regulated. Aging and chronic injury are major determinants of cancer risk. However, how declining tissue integrity reshapes the fitness of cells harboring oncogenic mutations remains poorly understood. Here we show that mutant β-catenin as a single genetic event confers negative fitness in the healthy liver of male mice, where mutant hepatocytes fail to clonally expand and undergo progressive attrition associated with oxidative and endoplasmic reticulum stress. In contrast, as liver tissue integrity declines during chronic injury or aging, cells carrying the same β-catenin mutation clonally expand and promote tumorigenesis, a process linked with activation of the AKT-NRF2 axis. These findings demonstrate that β-catenin mutations acting as single genetic lesions are maladaptive under normal liver homeostasis but become adaptive as tissue integrity deteriorates. This tissue-level shift reshapes the oncogenic fitness landscape, relaxing the constraints that normally prevent tumor initiation.

Indexed as

beta CateninCarcinogenesisLiverLiver NeoplasmsAgingAnimalsCarcinoma, HepatocellularCell Transformation, NeoplasticEndoplasmic Reticulum StressHepatocytesMaleMiceMice, Inbred C57BLMutationNF-E2-Related Factor 2Oxidative Stressbeta CateninCTNNB1 protein, mouseNfe2l2 protein, mouseNF-E2-Related Factor 2Proto-Oncogene Proteins c-akt

Identifiers

PMID42706261
PMCPMC13550535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.